BOSTON SCIENTIFIC CORP (BSX) Factsheet
BOSTON SCIENTIFIC CORP (BSX) Stock Analysis
Analysis from 10-Q filed 2025-11-03. Data as of Q1 2026.
Overall Grade: F (Concerning)
Grade F (Concerning). ROIC 10.3%. FCF margin 16.9%. D/E 0.4x. Source: 10-Q filed 2025-11-03.
| Metric | Value | Context |
|---|---|---|
| ROIC | 10.3% | Near cost of capital |
| FCF Margin | 16.9% | Strong cash generation |
| Debt/Equity | 0.4x | Conservative leverage |
ROIC 10.3% — Top 50% of sector peers. FCF margin 16.9% — Top 5%.
Explore BOSTON SCIENTIFIC CORP: Earnings History | Filings | ROIC Analysis
Programmatic access: Available via MCP at mcp.metricduck.com. Tools for BSX: get_company_overview, get_filing_index (lens: debt_stress, management_outlook, risk_trajectory), get_filing_changes, get_metric_history, compare_companies, screen_filing_signals.
Profitability: BOSTON SCIENTIFIC CORP earns 10.3% ROIC, Top 50% in Healthcare
ROIC TTM 10.3%, sector median -2.5%, Top 50%. DuPont: NOPAT margin 17.5% × asset turnover 0.5x. Gross margin 69.2%. Operating margin 18.4%. Source: 10-Q filed 2025-11-03.
| Metric | BSX | Rating | Context |
|---|---|---|---|
| Return on Invested Capital (ROIC) | 10.3% | Adequate | Above sector median of -2.5% |
| Return on Equity (ROE) | 15.2% | Good | Efficient use of shareholder equity |
| Gross Margin | 69.2% | Excellent | Strong pricing power |
| Operating Margin | 18.4% | Good | Efficient operations |
Cash Flow: BOSTON SCIENTIFIC CORP generates $3.5B FCF at 16.9% margin, positive NaN/8 quarters
FCF TTM $3.5B. FCF margin 16.9%, Top 5%. OCF/Net income 1.2x. Positive FCF in NaN/8 trailing quarters. Source: 10-Q filed 2025-11-03.
| Metric | BSX | Rating | Context |
|---|---|---|---|
| Free Cash Flow Margin | 16.9% | Good | Excellent cash conversion |
| Free Cash Flow (TTM) | $3.5B | Good | Positive cash generation |
| OCF/Net Income | 1.2x | Excellent | High earnings quality |
| FCF Consistency (8Q) | N/A | Warning | Variable cash flow |
Balance Sheet: BOSTON SCIENTIFIC CORP at 0.4x leverage
Debt/Equity 0.4x. Total debt $11.0B, cash & investments $1.6B. Source: 10-Q filed 2025-11-03.
| Metric | BSX | Rating | Context |
|---|---|---|---|
| Debt to Equity | 0.4x | Good | Conservative capital structure |
| Net Cash Position | $-9.4B | Warning | Net debt position |
Valuation: BOSTON SCIENTIFIC CORP trades at 26.1x earnings
P/E 26.1x. EV/Sales 5.0x. FCF yield 3.7%. Source: 10-Q filed 2025-11-03.
| Metric | BSX | Rating | Context |
|---|---|---|---|
| P/E Ratio | 26.1x | Adequate | Premium valuation |
| EV/Sales | 5.0x | Good | Growth premium priced in |
| FCF Yield | 3.7% | Adequate | Lower cash yield |
Capital Allocation: BOSTON SCIENTIFIC CORP returns 0.0% shareholder yield
Total shareholder yield 0.0%. Capital returned $0 TTM. Source: 10-Q filed 2025-11-03.
| Metric | BSX | Rating | Context |
|---|---|---|---|
| Total Shareholder Yield | 0.0% | Warning | Dividend + buyback yield combined |
| Total Capital Returned (TTM) | $0 | Adequate | Dividends + buybacks returned to shareholders |
Sector Rankings
| Metric | Value | Percentile | vs Median |
|---|---|---|---|
| Return on Invested Capital (ROIC) | 10.3% | Top 50% | - |
| Free Cash Flow Margin | 16.9% | Top 5% | - |
| Gross Margin | 69.2% | Top 50% | 1.1x above |
| Operating Margin | 18.4% | Top 25% | 8.0x above |
| Return on Equity (ROE) | 15.2% | Top 25% | - |
| P/E Ratio | 26.1x | N/A | - |
Financial Scorecard
| Metric | BSX | Rating | Sector Context |
|---|---|---|---|
| Return on Invested Capital (ROIC) | 10.3% | Adequate | Top 50% of sector (median: -2.5%) |
| Free Cash Flow Margin | 16.9% | Good | Top 5% of sector (median: 0.0%) |
| Gross Margin | 69.2% | Excellent | Top 50% of sector (median: 64.7%) |
| Debt to Equity Ratio | 42.6% | Good | Moderate leverage |
| P/E Ratio (Price-to-Earnings) | 26.1x | Adequate | Growth premium |
| Free Cash Flow Yield | 3.7% | Adequate | Moderate yield |
Frequently Asked Questions
Q: What is BOSTON SCIENTIFIC CORP's Return on Invested Capital (ROIC)?
BOSTON SCIENTIFIC CORP (BSX) has a trailing twelve-month Return on Invested Capital (ROIC) of 10.3%. Sector median -2.5%. Source: 10-Q filed 2025-11-03.
Q: What is BOSTON SCIENTIFIC CORP's Free Cash Flow Margin?
BOSTON SCIENTIFIC CORP (BSX) has a free cash flow margin of 16.9%, generating $3.5 billion in free cash flow over the trailing twelve months. Source: 10-Q filed 2025-11-03.
Q: What is BOSTON SCIENTIFIC CORP's P/E ratio and how does it compare to peers?
BOSTON SCIENTIFIC CORP (BSX) trades at a P/E ratio of 26.1x, which is above the sector median of N/A. EV/Sales 5.0x. FCF yield 3.7%. Source: 10-Q filed 2025-11-03.
Q: What is BOSTON SCIENTIFIC CORP's revenue and earnings growth?
BOSTON SCIENTIFIC CORP (BSX) grew revenue by 17.4% year-over-year. EPS +74.7% YoY. Source: 10-Q filed 2025-11-03.
Q: How does BOSTON SCIENTIFIC CORP compare to competitors in Healthcare?
Compared to other companies in Healthcare, BOSTON SCIENTIFIC CORP (BSX) shows: ROIC 10.3%, sector median -2.5% (Top 50%). FCF margin 16.9%, sector median 0.0% (Top 5%). Gross margin 69.2%, 4.4pp above sector median. These rankings are based on MetricDuck's analysis of all Healthcare companies with available SEC filings.
Q: What warning signs should I watch for with BOSTON SCIENTIFIC CORP?
No quantitative warning flags fired for BOSTON SCIENTIFIC CORP (BSX) on margin trend, FCF trend, ROIC trend, or leverage thresholds. Source: 10-Q filed 2025-11-03.
Data Source: Data sourced from 10-Q filed 2025-11-03. TTM metrics as of Q1 2026.
Methodology: Financial metrics calculated from SEC 10-K and 10-Q filings using standardized formulas. Sector comparisons use peer group based on SIC code.
Scope: This analysis covers SEC filing fundamentals — profitability, cash flow, balance sheet, and valuation metrics. For analyst estimates and price targets, consult sell-side research.
This analysis is for informational purposes only and does not constitute investment advice.